DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder

Information source: Sepracor, Inc.
Information obtained from ClinicalTrials.gov on October 19, 2007
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Insomnia Associated With Generalized Anxiety Disorder

Intervention: Eszopiclone (Lunesta) (Drug)

Phase: Phase 4

Status: Active, not recruiting

Sponsored by: Sepracor, Inc.

Summary

To determine the safety and efficacy of eszopiclone as adjunctive therapy in the treatment of insomnia in patients with insomnia related to Generalized Anxiety Disorder. All subjects will receive an approved anxiolytic agent and will be randomized to nightly therapy with either eszopiclone or placebo.

Clinical Details

Study design: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study

Eligibility

Minimum age: 18 Years. Maximum age: 64 Years. Gender(s): Both.

Criteria:

Inclusion Criteria: Subjects, between the ages of 18 and 64 years inclusive, with Generalized Anxiety Disorder and insomnia related to GAD.

Locations and Contacts

Birmingham, Alabama, United States

Mesa, Arizona, United States

Scottsdale, Arizona, United States

San Diego, California, United States

Redlands, California, United States

National City, California, United States

Orange, California, United States

Oceanside, California, United States

Irvine, California, United States

La Mesa, California, United States

Pasadena, California, United States

Riverside, California, United States

Farmington, Connecticut, United States

Washington, District of Columbia, United States

Fort Lauderdale, Florida, United States

St. Petersburg, Florida, United States

Gainesville, Florida, United States

Coral Springs, Florida, United States

Jacksonville, Florida, United States

Pembroke Pines, Florida, United States

Orlando, Florida, United States

Atlanta, Georgia, United States

Smyrna, Georgia, United States

Augusta, Georgia, United States

Northfield, Illinois, United States

Indianapolis, Indiana, United States

Owensboro, Kentucky, United States

Rockville, Maryland, United States

Baltimore, Maryland, United States

Cambridge, Massachusetts, United States

Brockton, Massachusetts, United States

Brighton, Massachusetts, United States

Braintree, Massachusetts, United States

Watertown, Massachusetts, United States

St. Louis, Missouri, United States

Kenilworth, New Jersey, United States

Piscataway, New Jersey, United States

New York, New York, United States

Lawrence, New York, United States

Brooklyn, New York, United States

Durham, North Carolina, United States

Winston-Salem, North Carolina, United States

Raleigh, North Carolina, United States

Bismarck, North Dakota, United States

Beachwood, Ohio, United States

Cincinnati, Ohio, United States

Dayton, Ohio, United States

Middleburg Heights, Ohio, United States

Eugene, Oregon, United States

Salem, Oregon, United States

Portland, Oregon, United States

Philadelphia, Pennsylvania, United States

Moon Township, Pennsylvania, United States

Scotland, Pennsylvania, United States

Columbia, South Carolina, United States

Memphis, Tennessee, United States

Austin, Texas, United States

San Antonio, Texas, United States

Houston, Texas, United States

Richardson, Texas, United States

Wichita Falls, Texas, United States

Richmond, Virginia, United States

Falls Church, Virginia, United States

Middleton, Wisconsin, United States

Additional Information


Last updated: May 31, 2006

Page last updated: October 19, 2007

-- advertisement -- The American Red Cross
We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2009